This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kessler, O. Articles by Neufeld, G. Search for Related Content PubMed PubMed Citation Articles by Kessler, O. Articles by Neufeld, G.

Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis

¹ Department of Cell Biology and Anatomy, Rappaport Family Institute for Research in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology; ² Department of Pathology, Carmel Medical Center; and ³ Department of Biotechnology and Food Engineering, Technion-Institute of Technology, Haifa, Israel

The neuropilin-1 (np1) and neuropilin-2 (np2) receptors form complexes with type-A plexins. These complexes serve as signaling receptors for specific class-3 semaphorins. Np1 and np2 function in addition as receptors for heparin-binding forms of vascular endothelial growth factor (VEGF), such as VEGF₁₆₅. Human umbilical vein endothelial cells (HUVEC) express tyrosine-kinase receptors for VEGF and basic fibroblast growth factor (bFGF), as well as np1, np2, and several type-A plexins. We have found that semaphorin-3F (s3f), a semaphorin which signals through the np2 receptor, was able to inhibit VEGF₁₆₅, as well as bFGF-induced proliferation of HUVECs. Furthermore, s3f inhibited VEGF as well as bFGF-induced phosphorylation of extracellular signal-regulated kinase-1/2. Our experiments indicate that bFGF does not bind to neuropilins, nor does s3f inhibit the binding of bFGF to FGF receptors. It is therefore possible that s3f inhibits the activity of bFGF by a mechanism that requires active s3f signal transduction rather than by inhibition of bFGF binding to FGF receptors. s3f also inhibited VEGF₁₆₅, as well as bFGF-induced in vivo angiogenesis as determined by the alginate micro-encapsulation and Matrigel plug assays. Overexpression of s3f in tumorigenic human HEK293 cells inhibited their tumor-forming ability but not their proliferation in cell culture. The tumors that did develop from s3f-expressing HEK293 cells developed at a much slower rate and had a significantly lower concentration of tumor-associated blood vessels, indicating that s3f is an inhibitor of tumor angiogenesis.

This article has been cited by other articles:

				P. Gaur, D. R. Bielenberg, S. Samuel, D. Bose, Y. Zhou, M. J. Gray, N. A. Dallas, F. Fan, L. Xia, J. Lu, et al. Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis Clin. Cancer Res., November 15, 2009; 15(22): 6763 - 6770. [Abstract] [Full Text] [PDF]

				L. Capparuccia and L. Tamagnone Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin J. Cell Sci., June 1, 2009; 122(11): 1723 - 1736. [Abstract] [Full Text] [PDF]

				A. Shimizu, A. Mammoto, J. E. Italiano Jr., E. Pravda, A. C. Dudley, D. E. Ingber, and M. Klagsbrun ABL2/ARG Tyrosine Kinase Mediates SEMA3F-induced RhoA Inactivation and Cytoskeleton Collapse in Human Glioma Cells J. Biol. Chem., October 3, 2008; 283(40): 27230 - 27238. [Abstract] [Full Text] [PDF]

				A. Varshavsky, O. Kessler, S. Abramovitch, B. Kigel, S. Zaffryar, G. Akiri, and G. Neufeld Semaphorin-3B Is an Angiogenesis Inhibitor That Is Inactivated by Furin-Like Pro-Protein Convertases Cancer Res., September 1, 2008; 68(17): 6922 - 6931. [Abstract] [Full Text] [PDF]

				C. Rolny, L. Capparuccia, A. Casazza, M. Mazzone, A. Vallario, A. Cignetti, E. Medico, P. Carmeliet, P. M. Comoglio, and L. Tamagnone The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment J. Exp. Med., May 12, 2008; 205(5): 1155 - 1171. [Abstract] [Full Text] [PDF]

				G. Serini, L. Napione, M. Arese, and F. Bussolino Besides adhesion: new perspectives of integrin functions in angiogenesis Cardiovasc Res, May 1, 2008; 78(2): 213 - 222. [Abstract] [Full Text] [PDF]

				L. M. Acevedo, S. Barillas, S. M. Weis, J. R. Gothert, and D. A. Cheresh Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor Blood, March 1, 2008; 111(5): 2674 - 2680. [Abstract] [Full Text] [PDF]

				V. A. Potiron, G. Sharma, P. Nasarre, J. A. Clarhaut, H. G. Augustin, R. M. Gemmill, J. Roche, and H. A. Drabkin Semaphorin SEMA3F Affects Multiple Signaling Pathways in Lung Cancer Cells Cancer Res., September 15, 2007; 67(18): 8708 - 8715. [Abstract] [Full Text] [PDF]

				N. Guttmann-Raviv, N. Shraga-Heled, A. Varshavsky, C. Guimaraes-Sternberg, O. Kessler, and G. Neufeld Semaphorin-3A and Semaphorin-3F Work Together to Repel Endothelial Cells and to Inhibit Their Survival by Induction of Apoptosis J. Biol. Chem., September 7, 2007; 282(36): 26294 - 26305. [Abstract] [Full Text] [PDF]

				J. M. Vieira, Q. Schwarz, and C. Ruhrberg Selective requirements for NRP1 ligands during neurovascular patterning Development, May 15, 2007; 134(10): 1833 - 1843. [Abstract] [Full Text] [PDF]

				N. Shraga-Heled, O. Kessler, C. Prahst, J. Kroll, H. Augustin, and G. Neufeld Neuropilin-1 and neuropilin-2 enhance VEGF121 stimulated signal transduction by the VEGFR-2 receptor FASEB J, March 1, 2007; 21(3): 915 - 926. [Abstract] [Full Text] [PDF]

				M. Futamura, H. Kamino, Y. Miyamoto, N. Kitamura, Y. Nakamura, S. Ohnishi, Y. Masuda, and H. Arakawa Possible Role of Semaphorin 3F, a Candidate Tumor Suppressor Gene at 3p21.3, in p53-Regulated Tumor Angiogenesis Suppression Cancer Res., February 15, 2007; 67(4): 1451 - 1460. [Abstract] [Full Text] [PDF]

				A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma Blood, September 1, 2006; 108(5): 1661 - 1667. [Abstract] [Full Text] [PDF]

				B. Favier, A. Alam, P. Barron, J. Bonnin, P. Laboudie, P. Fons, M. Mandron, J.-P. Herault, G. Neufeld, P. Savi, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration Blood, August 15, 2006; 108(4): 1243 - 1250. [Abstract] [Full Text] [PDF]

				T. Karpanen, C. A. Heckman, S. Keskitalo, M. Jeltsch, H. Ollila, G. Neufeld, L. Tamagnone, and K. Alitalo Functional interaction of VEGF-C and VEGF-D with neuropilin receptors FASEB J, July 1, 2006; 20(9): 1462 - 1472. [Abstract] [Full Text] [PDF]

				J. R. Basile, R. M. Castilho, V. P. Williams, and J. S. Gutkind Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis PNAS, June 13, 2006; 103(24): 9017 - 9022. [Abstract] [Full Text] [PDF]

				L. M. Ellis The role of neuropilins in cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1099 - 1107. [Abstract] [Full Text] [PDF]

				C. Christensen, N. Ambartsumian, G. Gilestro, B. Thomsen, P. Comoglio, L. Tamagnone, P. Guldberg, and E. Lukanidin Proteolytic Processing Converts the Repelling Signal Sema3E into an Inducer of Invasive Growth and Lung Metastasis Cancer Res., July 15, 2005; 65(14): 6167 - 6177. [Abstract] [Full Text] [PDF]

				V. Potiron and J. Roche Class 3 Semaphorin Signaling: The End of a Dogma Sci. Signal., May 24, 2005; 2005(285): pe24 - pe24. [Abstract] [Full Text] [PDF]

				A. Eichmann, T. Makinen, and K. Alitalo Neural guidance molecules regulate vascular remodeling and vessel navigation Genes & Dev., May 1, 2005; 19(9): 1013 - 1021. [Abstract] [Full Text] [PDF]

				A. Sahay, C.-H. Kim, J. P. Sepkuty, E. Cho, R. L. Huganir, D. D. Ginty, and A. L. Kolodkin Secreted Semaphorins Modulate Synaptic Transmission in the Adult Hippocampus J. Neurosci., April 6, 2005; 25(14): 3613 - 3620. [Abstract] [Full Text] [PDF]

				G. Serini and F. Bussolino Common Cues in Vascular and Axon Guidance Physiology, December 1, 2004; 19(6): 348 - 354. [Abstract] [Full Text] [PDF]

				A. R. Reynolds, L. E. Reynolds, T. E. Nagel, J. C. Lively, S. D. Robinson, D. J. Hicklin, S. C. Bodary, and K. M. Hodivala-Dilke Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in {beta}3-Integrin-Deficient Mice Cancer Res., December 1, 2004; 64(23): 8643 - 8650. [Abstract] [Full Text] [PDF]